{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:50:09Z","timestamp":1771235409883,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006970","name":"Ikaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018937","name":"Bavarian Nordic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1053\/j.gastro.2016.07.020","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T09:22:10Z","timestamp":1469524930000},"page":"651-659.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis"],"prefix":"10.1053","volume":"151","author":[{"given":"Edward","family":"Gane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Y.","family":"Kwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-4918","authenticated-orcid":false,"given":"Jacob","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Wyles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humberto","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict","family":"Maliakkal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa I.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-6886","authenticated-orcid":false,"given":"Jens","family":"Kort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.07.020_bib1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.07.020_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.07.020_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/hep.24370","article-title":"A\u00a0prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C","volume":"54","author":"Dienstag","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.07.020_bib4","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.21440","article-title":"Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial","volume":"44","author":"Everson","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.07.020_bib5","first-page":"218","article-title":"Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with hepatitis C infection","volume":"60","author":"Hill","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.07.020_bib6","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available from: http:\/\/www.hcvguidelines.org. Accessed: January 29,\u00a02016."},{"key":"10.1053\/j.gastro.2016.07.020_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.07.020_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2016.07.020_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.07.020_bib10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2016.07.020_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2016.07.020_bib12","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.07.020_bib13","first-page":"225","article-title":"Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program","volume":"62","author":"Welzel","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.07.020_bib14","first-page":"314A","article-title":"Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program","volume":"62","author":"H\u00e9zode","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.07.020_bib15","unstructured":"VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]. Revised October 2015. North Chicago, IL: AbbVie."},{"key":"10.1053\/j.gastro.2016.07.020_bib16","unstructured":"ZEPATIER (elbasvir and grazoprevir) tablets, for oral use [package insert]. Revised January 2016. Whitehouse Station, NJ: Merck & Co."},{"key":"10.1053\/j.gastro.2016.07.020_bib17","unstructured":"HARVONI (ledipasvir and sofosbuvir) tablets [package insert]. Revised March 2015. Foster City, CA: Gilead Sciences."},{"key":"10.1053\/j.gastro.2016.07.020_bib18","unstructured":"DAKLINZA (daclatasvir) tablets, for oral use [package insert]. Revised July 2015. Princeton, NJ: Bristol-Myers Squibb."},{"key":"10.1053\/j.gastro.2016.07.020_bib19","unstructured":"OLYSIO (simeprevir) capsules, for oral use [package insert]. Revised October 2015. Titusville, NJ: Johnson & Johnson."},{"key":"10.1053\/j.gastro.2016.07.020_bib20","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.07.020_bib21","unstructured":"Ng T, Krishnan P, Kati W, et\u00a0al. ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance. Available from: http:\/\/www.croiconference.org\/sites\/default\/files\/posters\/639.pdf. Accessed: January 20,\u00a02016."},{"key":"10.1053\/j.gastro.2016.07.020_bib22","unstructured":"Ng T, Reisch T, Middleton T, et\u00a0al. ABT-493, a potent HCV NS3\/4A protease inhibitor with broad genotype coverage.\u00a0Available from: http:\/\/www.croiconference.org\/sites\/default\/files\/posters\/636.pdf. Accessed: January 20, 2016."},{"key":"10.1053\/j.gastro.2016.07.020_bib23","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.02264-15","article-title":"Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection","volume":"60","author":"Lawitz","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2016.07.020_bib24","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2016.07.020_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2016.07.020_bib26","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In\u00a0vitro antiviral activity and resistance profile characterization of the HCV NS5A inhibitor ledipasvir","volume":"60","author":"Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2016.07.020_bib27","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/S0168-8278(15)31096-5","article-title":"Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816\u00a0+\/- ribavirin for 12 weeks","volume":"62","author":"Doehle","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.07.020_bib28","doi-asserted-by":"crossref","unstructured":"Ng T, Pilot-Matias T, Tripathi R, et\u00a0al. Analysis of HCV genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. J Hepatol 2016;64:S409-410.","DOI":"10.1016\/S0168-8278(16)00653-X"},{"key":"10.1053\/j.gastro.2016.07.020_bib29","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/jac\/dkv122","article-title":"Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin","volume":"70","author":"Rower","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2016.07.020_bib30","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0168-8278(15)30154-9","article-title":"Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study","volume":"62","author":"Poordad","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.07.020_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In\u00a0vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2016.07.020_bib32","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.07.020_bib33","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/v7092857","article-title":"Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance","volume":"7","author":"Cuypers","year":"2015","journal-title":"Viruses"},{"key":"10.1053\/j.gastro.2016.07.020_bib34","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2016.07.020_bib35","unstructured":"Zeuzem S, Mizokami A, Pianko S, et\u00a0al. Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV\/SOF. Hepatology 2015;64:254A-255A."},{"key":"10.1053\/j.gastro.2016.07.020_bib36","unstructured":"Jacobson IM, Asante-Appiah E, Wong P, et\u00a0al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection. Presented at American Association for the Study of Liver Diseases, San Francisco, CA, November 13\u201317,\u00a02015."},{"key":"10.1053\/j.gastro.2016.07.020_bib37","doi-asserted-by":"crossref","unstructured":"Kwo PY, Poordad F, Porcalla A, et\u00a0al. Safety of ABT-493 and ABT-530 co-administered in patients with HCV genotype 1\u20136 infection: results from the SURVEYOR-I and SURVEYOR-II studies. J Hepatol 2016;64:S809.","DOI":"10.1016\/S0168-8278(16)01579-8"},{"key":"10.1053\/j.gastro.2016.07.020_bib38","first-page":"S405","article-title":"Pharmacokinetics, safety, and tolerability of next generation direct acting antivirals ABT-493 and ABT-530 in subjects with renal impairment","volume":"64","author":"Kosloski","year":"2016","journal-title":"J\u00a0Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516348168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516348168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:42:36Z","timestamp":1762162956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508516348168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0016508516348168"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.07.020","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}